FDA Clearance Tracker · P980033
WALLSTENT ENDOPROSTHESIS
Last checked: Nov 20, 2026Latest source record: Nov 16, 2001 (this decision)Source: openFDAMethods & limitations
Decided
Nov 16, 2001
Approved
Time to decision
1,201 days
Received Aug 3, 1998. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P980033
- Device name
- WALLSTENT ENDOPROSTHESIS
- Applicant
- Boston Scientific Corporation
- Applicant location
- Maple Grove, MN
- Received
- Aug 3, 1998
- Decided
- Nov 16, 2001
- Decision
- Approved
- Supplements
- 65 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Stent, central venous (QKJ)
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE WALLSTENT VENOUS ENDOPROSTHESIS WITH UNISTEP PLUS RP DELIVERY SYSTEM (10 MM VENOUS ENDOPROSTHESIS) AND THE WALLSTENT VENOUS ENDOPROSTHESIS WITH UNISTEP PLUS DELIVERY SYSTEMS (12 MM - 16 MM VENOUS ENDOPROSTHESES). THESE DEVICES ARE INDICATED FOR IMPROVING CENTRAL VENOUS LUMINAL DIAMETER FOLLOWING UNSECCESSFUL ANGIOPLASTY IN PATIENTS ON CHRONIC HEMODIALYSIS WITH STENOSIS OF THE VENOUS OUTFLOW TRACT. UNSUCCESSFUL ANGIOPLASTY IS DEFINED AS RESIDUAL STENOSIS >= 30 PERCENT FOR A VEIN <= 10 MM IN DIAMETER OR >= 50 PERCENT FOR A VEIN > 10 MM IN DIAMETER, A TEAR WHICH INTERRUPTS THE INTEGRITY OF THE INTIMA OR LUMEN, ABRUPT LESION SITE OCCLUSION, OR REFRACTORY SPASM. THE VESSELS THAT CAN BE TREATED WITH THE DEVICE ARE THE INNOMINATE AND SUBCLAVIAN VEINS RANGING FROM 8 MM TO 15 MM IN DIAMETER.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code QKJ (Stent, central venous).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Boston Scientific Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- SpaceOAR Flex System510(k)
K262151 · Decided Sep 11, 2026 · 78 days after receipt
Device type: Hydrogel Spacer (OVB) · Radiology & Imaging
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.